Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation

This study has been completed.
Information provided by (Responsible Party):
Bay State Clinical Trials, Inc. Identifier:
First received: December 5, 2008
Last updated: May 12, 2014
Last verified: May 2014

Avodart (dutasteride) reduces the male hormone (DHT) that leads to prostate growth and stimulates cancerous growth. Avodart is currently approved by the FDA to treat men with symptoms of an enlarged prostate. Avodart works by reducing DHT and prostate size; therefore, the drug may be useful in improving lower urinary tract symptoms (LUTS) such as frequency, urgency, weak stream, and urination difficulty (dysuria), among others, in men with prostate cancer. Avodart may be effective in men with prostate cancer who are being treated with hormonal therapy with one injection of Zolodex (goserelin) followed one month later with a trans-urethral incision of the prostate (TUIP), and three months after that, seed implantation (SI) of the prostate.

The purpose of this study is to test whether Avodart (dutasteride) is effective on LUTS and dysuria in men with localized prostate cancer being treated with single-dose goserelin, TUIP, and interval SI.

Condition Intervention Phase
Prostate Cancer
Drug: avodart
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Placebo-Controlled Trial Assessing The Efficacy And Safety Of Dutasteride At Improving Lower Urinary Tract Symptoms In Men With Clinically Localized Prostate Cancer Being Treated With Single-Dose Goserelin, Trans-Urethral Incision Of Prostate, And Interval Brachytherapy

Resource links provided by NLM:

Further study details as provided by Bay State Clinical Trials, Inc.:

Primary Outcome Measures:
  • the effect of dutasteride on dysuria, voiding and LUTS [ Time Frame: 16 months ] [ Designated as safety issue: Yes ]

Enrollment: 40
Study Start Date: January 2009
Study Completion Date: April 2014
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 0.5mg Avodart
.5mg avodart capsule orally once a day during 13 months
Drug: avodart
0.5 avodart once daily for 13 weeks
Other Name: dutasteride
Placebo Comparator: Placebo
placebo capsule orally daily for 13 months
Drug: Placebo

Detailed Description:
Dutasteride is an inhibitor of the 5 alpha reductase type I and type II enzymes that convert testosterone to DHT, the male hormone that leads to benign prostate growth and drives malignant growth. Dutasteride has been shown to significantly decrease intraprostatic DHT in men with localized prostate cancer, and additionally cause apoptosis and regression of some prostate cancers [Andriole, 2004a; Andriole, 2004b]. Furthermore, reduction in tumor volume has also been demonstrated in human prostate tissue [Iczkowski, 2004]. Dutasteride is currently indicated to treat symptomatic BPH in men with enlarged prostates, but is also being studied to reduce the risk of prostate cancer in men at risk (elevated PSA and previous negative biopsy). Dutasteride is clinically useful at improving lower urinary tract symptoms (LUTS) in men with clinically-localized prostate cancer and voiding difficulty being treated with single-dose goserelin, TUIP, and interval SI. [Mitcheson, personal observation].

Ages Eligible for Study:   35 Years to 90 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:A subject will be eligible for inclusion in this study only if all of the following criteria apply:

  1. Must be male ≥35 and ≤90 years of age
  2. Have biopsy proven, localized prostate cancer
  3. Gleason score ≤ 8
  4. Clinical stage T1c-T2b
  5. Serum PSA (prostate specific antigen) ≤10ng/mL within the 12 months period prior to positive prostate biopsy.
  6. Able to swallow and retain oral medication
  7. Able and willing to participate in the full duration of the study
  8. Able to read and write (health outcomes questionnaires are self-administered), understand instructions related to study procedures and give written informed consent.

Exclusion Criteria:

  1. Subject has ever been treated for prostate cancer with any of the following:

    • Radiotherapy (external beam or brachytherapy)
    • Chemotherapy
    • Hormonal therapy (e.g., megestrol, medroxyprogesterone, cyproterone, diethyl-stilbestrol (DES)
    • Oral glucocorticoids
    • Gonadotropin Releasing Hormone (GnRH) analogues (e.g., leuprolide, goserelin) other than the single-dose gosereline given as treatment in this study.
  2. Glucocorticoids, except inhaled or topical, are not permitted within 3 months prior to visit one
  3. Current and/or previous use of the following medications:

    • Finasteride (Proscar, Propecia), or Dutasteride (Avodart) exposure within 6 months prior to study entry are excluded.
    • Any other investigational 5-reductase inhibitors within the past 12 months.
    • Anabolic steroids (subject must discontinued for 6 months prior to study entry to be eligible)
    • Drugs with antiandrogenic properties within the past 6 months (e.g,. spironolactone, flutamide, bicalutamide, *cimetidine, *ketoconazole, progestational agents) *The use of cimetidine is permitted prior to study entry. The use of topical ketoconazole is permitted prior to and during the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00805701

United States, Massachusetts
Bay State Clinical Trials, Inc.
Watertown, Massachusetts, United States, 02472
Sponsors and Collaborators
Bay State Clinical Trials, Inc.
Principal Investigator: Henry D Mitcheson, MD Bay State Clinical Trials, Inc.
  More Information

Responsible Party: Bay State Clinical Trials, Inc. Identifier: NCT00805701     History of Changes
Other Study ID Numbers: 047838 
Study First Received: December 5, 2008
Last Updated: May 12, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Bay State Clinical Trials, Inc.:

Additional relevant MeSH terms:
Lower Urinary Tract Symptoms
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms by Site
Prostatic Diseases
Signs and Symptoms
Urogenital Neoplasms
Urological Manifestations
5-alpha Reductase Inhibitors
Enzyme Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Steroid Synthesis Inhibitors processed this record on May 26, 2016